Bengaluru-based biotech major Biocon is working on multiple fronts — therapeutic vaccines, new drugs and ‘repurposing’ medicines — to tackle the Covid-19 pandemic. The company, with revenues of over Rs 5,600 crore, hopes to “repurpose” its existing novel biologic Itolizumab to treat complications caused by Covid-19, while another drug Cytosorb, […]

Tags